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2,618,862 participants reported their potential symptoms of COVID-19 on a smartphone-based 
app. Among the 18,401 who had undergone a SARS-CoV-2 test, the proportion of participants who 
reported loss of smell and taste was higher in those with a positive test result (4,668 of 7,178 
individuals; 65.03%) than in those with a negative test result (2,436 of 11,223 participants; 
21.71%); odds ratio= 6.74[95%CI 6.31; 7.21]. A model combining symptoms to predict likely 
infection was applied to data from all app users who report symptoms (805,753) and predicted 
that 140,312 (17.42%) participants are likely to have COVID-19.  
 
 
Since the outbreak of COVID-19, an acute respiratory illness caused by the novel coronavirus SARS-
CoV-2, in China in December 2019 until 21st April 2020, over 2,573,143 cases have been confirmed 
worldwide (https://www.worldometers.info/coronavirus/). Although many people have presented 
with flu-like symptoms, widespread population testing is not yet available in most countries, 
including the US (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/testing-in-us.html) 
and the UK1. Thus, it is important to identify the combination of symptoms most predictive of 
COVID-19 infection, to help to guide recommendations for self-isolation and prevent further spread 
of the disease2. 
Case reports and mainstream media articles from various countries indicate that a number of 
patients with diagnosed COVID-19 developed anosmia (loss of smell) 3,4. Mechanisms of action for 
the SARS-CoV-2 viral infection causing anosmia has been postulated 5,6. Other studies indicate that a 
number of infected individuals present anosmia in the absence of other symptoms7,8 suggesting that 
this symptom could be used as screening tool to help identify potential mild cases who could be 
recommended to self-isolate9.  
We investigated whether loss of smell and taste is specific to COVID-19 in 2,618,862 individuals who 
used an app-based symptom tracker10 (Methods). The symptom tracker is a free smartphone 
application that was launched in the UK on Tuesday the 24th March 2020, and in the US on 29th 
March 2020. It collects data from both asymptomatic and symptomatic individuals and tracks in real 
time how the disease progresses by recording self-reported health information on a daily basis, 
including symptoms, hospitalisation, RT-PCR test outcomes, demographic information and pre-
existing medical conditions  
 
Between March 24, 2020 and April 21, 2020, 2,450,569 UK and 168,293 US individuals reported 
symptoms through the smartphone app. Of the 2,450,569 participants in the UK, 789,083 (32.2%) 
indicated having one or more potential symptoms of COVID-19 (Table 1). 15,638 UK and 2,763 US 
app users reported having had an RT-PCR SARS-CoV-2 test, and having received the outcome of the 
test. In the UK cohort, 6,452 participants reported a positive test and 9,186 participants had a 
negative test. In the cohort from the UK, of the 6,452 participants who tested positive for SARS-CoV-
2, 4,178 participants (64.76%) reported loss of smell and taste compared with 2,083 out of 9,186 
participants (22.68%) who tested negative (OR[95%CI ]= 6.40[5.96; 6.87], P<0.0001, after adjusting 
for age, sex and BMI). We replicated this result in the US subset who had been tested for SARS-CoV-
2 (adjusted OR[95%CI] = 10.01[8.23;12.16], P <0.0001) and combined the adjusted results using 
inverse variance fixed effect meta-analysis (OR(95%CI] = 6.74[6.31; 7.21], P<0.0001).  
 
We reran logistic regressions adjusting for age, sex and BMI to identify other symptoms besides 
anosmia, which might be associated with being infected by SARS-CoV-2. All ten symptoms queried 
(fever, persistent cough, fatigue, shortness of breath, diarrhoea, delirium, skipped meals, abdominal 
pain, chest pain and hoarse voice) were associated with testing positive for COVID-19 in the UK 
cohort, after adjusting for multiple testing (Figure 1a). In the US cohort, only loss of smell and taste, 
fatigue and skipped meals were associated with a positive test result. 
We performed stepwise logistic regression in the UK cohort, by randomly dividing it into a training 
and test sets (ratio 80/20) to identify independent symptoms most strongly correlated to COVID-19 
adjusting for age, sex and BMI. A combination of loss of smell and taste, fatigue, persistent cough 
and loss of appetite resulted in the best model (with the lowest Akaike information criterion [AIC]). 
We therefore generated a linear model for symptoms that included loss of smell and taste, fatigue, 
persistent cough and loss of appetite to get a symptoms prediction model for COVID-19: 
Prediction model = -1.32 - (0.01 x age) + (0.44 x sex) + (1.75 x loss of smell and taste) + (0.31 x 
severe or significant persistent cough) + (0.49 x severe fatigue) + (0.39 x skipped meals)  
 
where all symptoms are coded as 1 if the person self-reports the symptom and 0 if not. The sex 
feature is also binary, with 1 indicative of male participants and 0 representing females. The 
obtained value is then transformed into predicted probability using exp(X)/(1+exp(X)) 
transformation followed by assigning cases of “predicted COVID-19” for probabilities > 0.5 and 
controls for probabilities <0.5. 
 
The prediction model had a sensitivity of 0.65[0.62; 0.67], a specificity of 0.78[0.76; 0.80], and a 
ROC-AUC 0.78[0.76; 0.82]. Cross-validation ROC-AUC was 0.75[0.74; 0.76] and positive predictive 
value was 0.69[0.66; 0.71] and negative predictive value was 0.75[0.73; 0.77]. In this model, the 
strongest predictor was loss of smell and taste, Figure 1b. Excluding loss of smell and taste from the 
model resulted in reduced sensitivity (0.33[0.30,0.35]) but increased specificity (0.84[0.83,0.86]). We 
also computed the ROC-AUC stratifying for sex and age-groups and found that results were similar in 
all groups with no significant differences between strata suggesting that our model works similarly 
within different sex and age groups. We validated the model in the US cohort and found a sensitivity 
of 0.66 [0.62, 0.69], a specificity of 0.83 [0.82, 0.85], a positive predictive value of 0.58 [0.55, 0.62] 
and a negative predictive value 0.87 [0.86, 0.89] (Figure 1c).  
We also queried if the association between loss of smell and taste and COVID-19 was influenced by 
mainstream media reports. We assessed the correlation between loss of smell and taste and being 
COVID-19 positive in different date ranges: (i) March 24 to April 3, 2020 following a number of 
reports in the UK mainstream media (eg: https://www.bbc.co.uk/news/health-52111606) reporting 
anosmia as a symptom of COVID-19, (ii) the week of April 4-10, 2020, and (iii) from April 11, 2020 to 
April 21. In the UK the OR[95%CI] for the associations of self-reported loss of smell and taste and a 
positive test for COVID-19 across these periods were 4.98[4.47;5.56], 6.64[5.75;7.68] and 10.40[ 9.08 
;11.91] respectively. However, this association was not found in the US cohorts: Mar24-Apr3 OR 
[95%CI] =8.13[5.18;12.78], Apr 4-10: 12.30[8.96;16.90] and Apr11-21: 9.13[6.73;12.38]. 
 
Finally, we applied the predictive model to the 608,385 UK and US individuals reporting symptoms 
who had not had a COVID-19 test and we find that according to our model 140,312 of 805,753 
participants, 17.42%[14.45%;20.39%], reporting some symptoms are likely to be infected by the 
virus, representing 5.36% as a proportion of the overall responders to the app.  
 
 
We report that loss of smell and taste is a potential predictor of COVID-19 in addition to other, more 
established, symptoms of high temperature and a new, persistent cough. COVID-19 appears to cause 
problems of smell receptors in line with many other respiratory viruses, including previous 
coronaviruses thought to account for 10-15% of cases of anosmia7,9. 
We also identify a combination of symptoms including anosmia, fatigue, persistent cough, and loss 
of appetite that together might identify individuals with COVID-19.  
 
A major limitation of the current study is the self-report nature of the data included, which cannot 
replace physiological assessments of olfactory and gustatory function, or nucleotide-based testing 
for SARS-CoV-2. Both false negative and false negative reports could be included in the data set11, 
and in addition, because of the way the questions are asked, gustatory and olfactory losses are 
conflated. Second, at present, we do not know whether anosmia was acquired prior to or following 
other COVID-19 symptoms, or during the illness or afterwards. This information could become 
available as currently healthy users track symptom development over time. As more accurate tests 
become available, we have the ability to optimise our model. One caveat of our study is that the 
individuals on which the model was trained are not representative of the general population 
because performing tests for SARS-CoV-2 is not random. Testing is more likely to be done if an 
individual develops severe symptoms requiring hospitalisation, if an individual has been known to 
have had contact with people who have tested positive for SARS-CoV-2 infectionCOVID-19, in health 
workers, and if an individual has travelled in an area of high risk of exposure. Therefore, our results 
may overestimate the number of expected positive cases of SARS-Cov2 infection. Additionally, 
volunteers using the app are a self-selected group who might not be fully representative of the 
general population. Another limitation is the potential effect that mainstream media coverage of 
loss of smell and taste and COVID-19 might have had on app responses. We find that these reports 
might have influenced UK responders where there is a temporal trend in the strength of the 
association, but not in the US cohort, therefore we conclude that regardless of any bias introduced 
by mainstream media reports, the association between COVID-19 and loss of smell and taste 
remains strong. 
 
Our work suggests that loss of sense of smell and taste could be included as part of routine 
screening for COVID-19 and should be added to the symptom list currently developed by the World 
Health Organization (www.who.int/health-topics/coronavirus). A detailed study on the natural 
history of broader COVID-19 symptoms, especially according to timing and frequency, will help to 
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Table 1. Characteristics of the study population. Results are presented as (%) for dichotomous 
traits, as mean(SD) for continuous traits 
  
 















N 6,452 9,186 726 2,037 2,434,931 165,530 
%Females 71.88% 76.40% 78.10% 82.28%  64.24% 68.67% 















6,452 9,186 726 2,037 773,539 32,214 
Loss of smell 
and taste 
64.76% 22.68% 67.49% 17.33% 9.5% 12.1% 
Fatigue 29.80%  15.56% 23.42% 21.50% 8.71% 8.17% 
Shortness of 
breath 
15.27% 9.37% 13.50% 12.03% 4.52% 3.65% 
Fever 34.34% 23.93% 27.74% 26.25% 9.31% 4.78% 
Persistent 
cough 
56.73% 45.56% 44.77% 41.24% 30.17% 22.25% 
Diarrhoea 25.95% 19.24% 32.92% 29.06% 19.33% 23.26% 
Delirium 17.87% 13.25% 23.55% 23.47% 15.26% 16.25% 
Skipped 
meals 
42.03% 24.93% 47.25% 36.08% 19.12% 21.42% 
Abdominal 
pain 
21.31% 18.24% 20.94% 21.06% 3.70% 15.94% 
Chest pain 42.73% 39.17% 38.57% 41.92% 18.65% 24.74% 




Figure 1. a. Association between symptoms and SARS-CoV-2 infection in 15,638 UK and 2,763 US 
participants who were tested via RT-PCR, OR(95%CI). b. ROC-curve for prediction in the UK test set 
of the risk of positive test for SARS-CoV-2 using self-reported symptoms and traits: persistent cough, 
fatigue, skipped meals, loss of smell and taste, sex, age. c ROC-curve for prediction in the US 
validation set of the risk of positive test for SARS-CoV-2 using self-reported symptoms and traits: 
persistent cough, fatigue, skipped meals, loss of smell and taste, sex, age. AUC=area under the curve; 
SE=sensitivity; SP=specificity; PPV=positive predictive value; NPV= negative predictive value. 
  
Online Methods 
Study setting and participants 
The COVID Symptom Tracker smartphone based app was developed by Zoe Global Limited, King’s 
College London, and Massachusetts General Hospital, and was launched in the UK on Tuesday the 
24th March 2020, and in the US on 29th March 2020 and after three weeks has reached 2,618,862 
users. It enables capture of self-reported information related to COVID-19 infections as described 
previously10. The survey questions are available in Supplemental Table 1. On first use, the app 
records self-reported location, age, and core health risk factors. With continued use and 
notifications, participants provide daily updates on symptoms, health care visits, COVID-19 testing 
results, and if they are self-quarantining or seeking health care, including the level of intervention 
and related outcomes. Individuals without apparent symptoms are also encouraged to use the app.  
Ethics: The Ethics for the app has been approved by KCL ethics Committee and all users provided 
consent for non-commercial use. An informal consultation with TwinsUK members over email and 
social media prior to the app having been launched found that they were overwhelmingly supportive 
of the project. The US protocol was approved by the Partners Human Research Committee. 
Statistical analysis  
Data from the app were downloaded into a server and only records where the self-reported 
characteristics fell within the following ranges were utilised for further analyses: age between 16 (18 
in the US) and 90; height (cm) between 110 and 220; weight (kg) between 40 and 200; BMI(kg/m2) 
between 14 and 45; and temperature (in C) between 35 and 42. The individuals whose data was 
included to develop and test the prediction model were those who completed the report for 
symptoms in the app, who declared to have had a SARS-CoV-2 RT-PCR test and to have received the 
result for the test. Only individuals who answered at least 9 of the 10 symptoms and answered 
about loss of smell and taste were included. 
Baseline characteristics are presented as the number (percentage) for categorical variables and the 
mean (standard deviation) for continuous variables. Multivariate logistic regression adjusting for 
age, sex and BMI was applied to investigate the correlation between loss of smell and taste and 
COVID-19 in 15,368 UK users of the symptom tracker app who were also tested in the lab for SARS-
CoV-2 (6,452 UK individual tested positive and 9,186 tested negative). Results were replicated in 726 
US individual tested positive and 2,037 US individual tested negative. We then randomly split the UK 
sample into training and test sets with 80/20 ratio. In the training set, we performed stepwise 
logistic regression combining forward and backward algorithms, to identify other symptoms 
associated to COVID-19 independently of loss of smell and taste. We included in the model ten other 
symptoms (including fever, persistent cough, fatigue, shortness of breath, diarrhoea, delirium, 
skipped meals, abdominal pain, chest pain and hoarse voice) as well as age, sex, and BMI and chose, 
as the best model, the one with the lowest AIC. We then assessed the performance of the model 
both it the test set and via 10-fold cross-validation in the whole UK sample of 15,638 individuals 
using the R package cvAUC12. We further validated the prediction model in the US cohort. 
For our predictive model, using the R packages pROC and epiR, we further computed the area under 
curve (AUC) i.e. the overall diagnostic performance of the model, the sensitivity (“positivity in 
disease”) i.e. the proportion of subjects who have the target condition (reference standard positive) 
and give positive test results, and the specificity (“negativity in health”) i.e. the proportion of 
subjects without a SARS-CoV-2 RT-PCR test that give negative model results. 
 Finally, we applied the predictive model to the 805,753 individuals reporting symptoms who had not 
had a SARS-CoV-2 test in order to estimate the percentage of individuals reporting some COVID-19 
symptoms likely to be infected by the virus. The proportion of estimated infections was calculated 
repeatedly by sampling the dataset (with replacement) to get the 95% confidence intervals. 
Reporting Summary 
Further information on research design is available in the Life Sciences Reporting Summary linked to 
this article. 
  
 
